Navigation Links
Idenix Announces Data Presentations at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
Date:10/1/2009

CAMBRIDGE, Mass., Oct. 1 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that two abstracts on IDX184, the company's lead hepatitis C development program, have been accepted for presentation at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD, October 30-November 3, 2009 in Boston, Massachusetts). Full abstracts can now be viewed at the AASLD website at www.aasld.org.

The accepted abstracts are as follows:

  • Lalezari, et al, "Antiviral Activity, Safety and Pharmacokinetics of IDX184, A Liver-Targeted Nucleotide HCV Polymerase Inhibitor, in Patients with Chronic Hepatitis C", will be presented in a late-breaking poster session on Monday, November 2 between 8:00 a.m. - 5:30 p.m.
  • Lallos, et al, "Combination of IDX184, a Nucleotide Prodrug Polymerase Inhibitor, With Other Classes of HCV Inhibitors is Additive to Synergistic in the HCV Replicon In Vitro" will be presented in a poster session entitled HCV Therapy: Preclinical and Clinical Development on Tuesday, November 3, 2009 between 8:00 a.m. - 1:00 p.m.

About Idenix

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of infections caused by hepatitis C virus. For further information about Idenix, please refer to www.idenix.com.

Forward-looking Statements

This press release contains "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward- looking statements can be identified by the use of forward-looking terminology such as "will" or similar expressions, or by express or implied statements with respect to the company's clinical development programs or commercialization activities in hepatitis C. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management's expectations could be affected by unexpected regulatory actions or delays; uncertainties relating to, or unsuccessful results of, clinical trials, including additional data relating to the ongoing clinical trials evaluating its product candidates; the company's ability to obtain additional funding required to conduct its research, development and commercialization activities; the company's dependence on third party collaborators, changes in the company's business plan or objectives; the ability of the company to attract and retain qualified personnel; competition in general; and the company's ability to obtain, maintain and enforce patent and other intellectual property protection for its product candidates and its discoveries. These and other risks which may impact management's expectations are described in greater detail under the caption "Risk Factors" in the company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2009 as filed with the Securities and Exchange Commission (SEC) and other filings that the company makes with the SEC.

All forward-looking statements reflect the company's expectations only as of the date of this release and should not be relied upon as reflecting the company's views, expectations or beliefs at any date subsequent to the date of this release. Idenix anticipates that subsequent events and developments may cause these views, expectations and beliefs to change. However, while Idenix may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.

    Idenix Pharmaceuticals Contact:
    Teri Dahlman (617) 995-9905

SOURCE Idenix Pharmaceuticals, Inc.


'/>"/>
SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs
2. Idenix to Host Conference Call Discussing Third Quarter 2007 Financial Results
3. Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
4. Idenix to Host Conference Call Discussing Fourth Quarter 2007 Financial Results
5. Idenix Announces Data Presentations at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL)
6. Idenix Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
7. Idenix Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
8. Idenix Pharmaceuticals to Present at the Seventh Annual Needham and Company, LLC Biotechnology and Medical Technology Conference
9. Idenix Pharmaceuticals Reports Second Quarter and Six Month Financial Results
10. Idenix Pharmaceuticals to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference
11. Idenix to Host Conference Call Discussing Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... ... LabRoots , the leading provider of scientific trending news and interactive ... a new textbook scholarship, the second scholarship in the LabRoots program. , This ... pursuing a degree in one of the life sciences. The scholarship will provide one ...
(Date:5/24/2017)... ... May 24, 2017 , ... Patient Monitoring ... with Wi-Fi connectivity to reduce the amount of wiring in a healthcare facility ... compact mobile devices including infusion pumps, heart and hypertension monitoring, glucose monitoring, and ...
(Date:5/23/2017)... ... May 23, 2017 , ... Genedata, a leading provider of ... occasion with a strong presence at Bio-IT World Conference & Expo 2017 in ... invitation to all attendees to view posters on the entire range of ...
(Date:5/23/2017)... ... 23, 2017 , ... Kathy Goin is joining myClin ... brings years of expertise in establishing and leading clinical operations at Sponsors including ... occupational therapist, through a variety of leadership roles in Clinical Operations, to her ...
Breaking Biology Technology:
(Date:3/28/2017)... 28, 2017 The report "Video ... Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), and ... Global Forecast to 2022", published by MarketsandMarkets, the market ... is projected to reach USD 75.64 Billion by 2022, ... The base year considered for the study is 2016 ...
(Date:3/23/2017)... , Mar. 23, 2017 Research and Markets ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... at a CAGR of around 8.8% over the next decade to ... report analyzes the market estimates and forecasts for all the given ...
(Date:3/20/2017)... March 20, 2017 PMD Healthcare announces the ... and Wellness Management System (WMS), a remote, real-time lung ... 2010, PMD Healthcare is a Medical Device, Digital Health, ... dedicated to creating innovative solutions that empower people to ... intent focus, PMD developed the first ever personal spirometer, ...
Breaking Biology News(10 mins):